Abstract:Abstract Background The p38 alpha mitogen‐activated protein kinase (p38α) pathway is linked to both innate and adaptive immune responses, and is currently under investigation as a target for drug development in the context of Alzheimer’s disease (AD) and other conditions with neuroinflammatory dysfunction (Asih et al., 2020). Preclinical data indicates that p38α inhibition can protect against AD‐associated neuropathology, although the cellular mechanisms and signaling pathways that underlie these effects have not been fully elucidated. Evidence suggests that inhibition of p38α may provide benefit by modulating microglial‐associated neuroinflammatory processes that contribute to the development of AD pathology. The present study tests this hypothesis by assessing early‐stage pathological changes in AD model mice following microglial‐specific knock out (KO) of p38α. Methods KO of p38α in microglia was accomplished in 5‐month‐old C57BL/6J wild‐type and amyloidogenic AD model (APPswe/PS1dE9) mice using a tamoxifen‐inducible Cre/loxP system under control of the Cx3Cr1 promoter. Animals underwent behavioral assessment on the open field test at 7.5 months of age and on the radial arm water maze test at 11 months of age, followed by collection of cortical and hippocampal tissues. Other endpoint measures included quantification of proinflammatory cytokines, assessment of amyloid burden and plaque deposition, and characterization of microglia‐plaque dynamics using a combination of ELISA, immunohistochemical, and immunofluorescent techniques. Results Suppression of microglial p38α did not alter behavioral outcomes, proinflammatory cytokine levels, or overall amyloid plaque burden, but did significantly increase hippocampal levels of soluble Aβ42 and reduced hippocampal colocalization of Iba1 and 6E10 in a subset of microglia in close proximity to plaques. Conclusion This work suggests that rather than reducing inflammation per se, microglial p38α inhibition in the context of early AD‐type amyloid pathology may alter hippocampal microglia‐plaque interactions. Additionally, these results support future investigations of microglial p38α signaling at different stages of disease, as well as the potential relationship between p38α and phagocytic processes in this particular cell‐type. Funding : This work is supported by the National Institutes of Health (RF1 AG064859; F32 AG058456; T32 AG057461).

Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer’s Disease

p38α Mitogen-Activated Protein Kinase—An Emerging Drug Target for the Treatment of Alzheimer's Disease

P38mapk: Novel Therapeutic Target to Slow the Progression of Alzheimers Disease

Involvement of p38 MAPK in Synaptic Function and Dysfunction

A small molecule p38α MAPK inhibitor, MW150, attenuates behavioral deficits and neuronal dysfunction in a mouse model of mixed amyloid and vascular pathologies

Natural Products Regulate the P38MAPK Signaling Pathway: A Promising Strategy in the Prevention and Treatment of Alzheimer’s Disease

The P38 Mitogen Activated Protein Kinase Regulates Β-Amyloid Protein Internalization Through the Α7 Nicotinic Acetylcholine Receptor in Mouse Brain.

Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ

Early loss of microglial p38α MAPK in the APPswe/PS1dE9 mouse model of Alzheimer’s disease alters soluble amyloid beta and reduces microglia co‐localization with amyloid plaques without affecting amyloid‐associated pathology

Targeting protein kinases for the treatment of Alzheimer's disease: Recent progress and future perspectives

Reduction of advanced tau‐mediated memory deficits by the MAP kinase p38γ

The Recent Updates of Therapeutic Approaches Against Aβ for the Treatment of Alzheimer's Disease

Exploring the Therapeutic Potential of BBB‐Penetrating Phytochemicals With p38 MAPK Modulatory Activity in Addressing Oxidative Stress‐Induced Neurodegenerative Disorders, With a Focus on Alzheimer's Disease

Novel Strategies for Inhibition of the P38 MAPK Pathway.

Recent trends in treatment strategies for Alzheimer's disease and the challenges: A topical advancement

The p38 mitogen-activated protein kinase signaling pathway is involved in regulating low-density lipoprotein receptor-related protein 1-mediated β-amyloid protein internalization in mouse brain

Therapeutic Potential of AMP-Activated Protein Kinase in Alzheimer’s Disease

Recent Advance on P38 Mitogen-Activated Protein Kinases Inhibitors

Pharmacological mTOR inhibitors in ameliorating Alzheimer's disease: current review and perspectives

P38 Activation Mediates Amyloid-Beta Cytotoxicity

Photobiomodulation suppresses JNK3 by activation of ERK/MKP7 to attenuate AMPA receptor endocytosis in Alzheimer's disease